BR112014029302A2 - método de redução de peso - Google Patents
método de redução de pesoInfo
- Publication number
- BR112014029302A2 BR112014029302A2 BR112014029302A BR112014029302A BR112014029302A2 BR 112014029302 A2 BR112014029302 A2 BR 112014029302A2 BR 112014029302 A BR112014029302 A BR 112014029302A BR 112014029302 A BR112014029302 A BR 112014029302A BR 112014029302 A2 BR112014029302 A2 BR 112014029302A2
- Authority
- BR
- Brazil
- Prior art keywords
- weight reduction
- reduction method
- glucose
- disclosure
- methazolamide
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000013585 weight reducing agent Substances 0.000 title abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000014101 glucose homeostasis Effects 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 abstract 1
- 229960004083 methazolamide Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651335P | 2012-05-24 | 2012-05-24 | |
| PCT/AU2013/000259 WO2013173858A1 (en) | 2012-05-24 | 2013-03-15 | A method of weight reduction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014029302A2 true BR112014029302A2 (pt) | 2017-06-27 |
Family
ID=49622926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014029302A BR112014029302A2 (pt) | 2012-05-24 | 2013-03-15 | método de redução de peso |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20150174108A1 (enExample) |
| EP (1) | EP2854806A4 (enExample) |
| JP (1) | JP6438389B2 (enExample) |
| KR (1) | KR20150023404A (enExample) |
| CN (1) | CN104582701B (enExample) |
| AU (1) | AU2013202981B2 (enExample) |
| BR (1) | BR112014029302A2 (enExample) |
| CA (1) | CA2874512A1 (enExample) |
| CO (1) | CO7160083A2 (enExample) |
| HK (1) | HK1209041A1 (enExample) |
| MX (1) | MX2014014316A (enExample) |
| NZ (1) | NZ702666A (enExample) |
| RU (1) | RU2664442C2 (enExample) |
| SG (1) | SG11201407786XA (enExample) |
| WO (1) | WO2013173858A1 (enExample) |
| ZA (1) | ZA201408703B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101801375B (zh) | 2007-01-25 | 2014-01-01 | 韦尔瓦制药有限公司 | 胰岛素增敏剂和治疗方法 |
| WO2013173859A1 (en) * | 2012-05-24 | 2013-11-28 | Verva Pharmaceuticals Ltd | A method of improving liver function |
| US10039752B2 (en) * | 2016-07-21 | 2018-08-07 | Cipla Limited | Methazolamide for the treatment of cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2783241A (en) * | 1957-02-26 | S-acylimino-x-substituted-az-i | ||
| JP2000080047A (ja) * | 1998-06-30 | 2000-03-21 | Takeda Chem Ind Ltd | 医 薬 |
| US6946243B2 (en) * | 2000-07-20 | 2005-09-20 | Solvay Pharmaceuticals Gmbh | Method of identifying compounds suitable for treatment and/or prophylaxis of obesity |
| DE60110087T2 (de) * | 2000-08-11 | 2005-09-29 | Einar Stefansson | Verwendung von Carboanhydrase-Inhibitoren zur Prävention von diabetischer Retinopathie bei Diabetikern |
| CN100415224C (zh) * | 2003-03-18 | 2008-09-03 | 诺瓦提斯公司 | 包含脂肪酸和氨基酸的组合物 |
| DE602004012403T2 (de) * | 2003-04-29 | 2009-03-19 | Orexigen Therapeutics, Inc., La Jolla | Zusammensetzungen zur beeinflussung des gewichtsverlusts |
| WO2005012243A2 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica N.V. | Substituted indole-o-glucosides |
| WO2007114948A2 (en) * | 2006-04-04 | 2007-10-11 | The Brigham And Women's Hospital, Inc. | Methods and compositions for inhibiting cell death |
| CN101801375B (zh) * | 2007-01-25 | 2014-01-01 | 韦尔瓦制药有限公司 | 胰岛素增敏剂和治疗方法 |
| TW201105338A (en) * | 2009-07-01 | 2011-02-16 | Kissei Pharmaceutical | Medicine derived from a combination of SGLT1-inhibitor and DPP-IV inhibitor |
| EP2585097B1 (en) * | 2010-06-25 | 2018-09-26 | Aston University | Glycoproteins having lipid mobilizing properties and therapeutic uses thereof |
| EP2583965B1 (en) * | 2010-07-15 | 2017-01-25 | Takeda Pharmaceutical Company Limited | Heterocyclic ring compound |
| WO2013173859A1 (en) * | 2012-05-24 | 2013-11-28 | Verva Pharmaceuticals Ltd | A method of improving liver function |
-
2013
- 2013-03-15 SG SG11201407786XA patent/SG11201407786XA/en unknown
- 2013-03-15 CA CA2874512A patent/CA2874512A1/en not_active Abandoned
- 2013-03-15 JP JP2015512967A patent/JP6438389B2/ja not_active Expired - Fee Related
- 2013-03-15 CN CN201380033658.6A patent/CN104582701B/zh not_active Expired - Fee Related
- 2013-03-15 MX MX2014014316A patent/MX2014014316A/es unknown
- 2013-03-15 AU AU2013202981A patent/AU2013202981B2/en not_active Ceased
- 2013-03-15 KR KR20147035499A patent/KR20150023404A/ko not_active Withdrawn
- 2013-03-15 HK HK15109728.3A patent/HK1209041A1/xx unknown
- 2013-03-15 RU RU2014150946A patent/RU2664442C2/ru not_active IP Right Cessation
- 2013-03-15 US US14/403,495 patent/US20150174108A1/en not_active Abandoned
- 2013-03-15 BR BR112014029302A patent/BR112014029302A2/pt not_active Application Discontinuation
- 2013-03-15 NZ NZ702666A patent/NZ702666A/en not_active IP Right Cessation
- 2013-03-15 EP EP13794519.2A patent/EP2854806A4/en not_active Withdrawn
- 2013-03-15 WO PCT/AU2013/000259 patent/WO2013173858A1/en not_active Ceased
-
2014
- 2014-11-26 ZA ZA2014/08703A patent/ZA201408703B/en unknown
- 2014-12-19 CO CO14279766A patent/CO7160083A2/es unknown
-
2018
- 2018-02-09 US US15/892,989 patent/US20180333398A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201408703B (en) | 2018-07-25 |
| KR20150023404A (ko) | 2015-03-05 |
| MX2014014316A (es) | 2015-07-06 |
| WO2013173858A1 (en) | 2013-11-28 |
| CA2874512A1 (en) | 2013-11-28 |
| JP6438389B2 (ja) | 2018-12-12 |
| US20180333398A1 (en) | 2018-11-22 |
| NZ702666A (en) | 2016-08-26 |
| CN104582701A (zh) | 2015-04-29 |
| CN104582701B (zh) | 2018-01-16 |
| JP2015520759A (ja) | 2015-07-23 |
| SG11201407786XA (en) | 2015-03-30 |
| CO7160083A2 (es) | 2015-01-15 |
| US20150174108A1 (en) | 2015-06-25 |
| AU2013202981A1 (en) | 2013-12-12 |
| EP2854806A4 (en) | 2015-11-18 |
| RU2014150946A (ru) | 2016-07-10 |
| EP2854806A1 (en) | 2015-04-08 |
| HK1209041A1 (en) | 2016-03-24 |
| AU2013202981B2 (en) | 2014-11-13 |
| RU2664442C2 (ru) | 2018-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014027571A2 (pt) | métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas | |
| BR112015009948A8 (pt) | Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios | |
| MY175997A (en) | Antl-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition | |
| BR112018000639A8 (pt) | Sistema de cateter funcionalmente integrável | |
| EA201590849A1 (ru) | Композиции, способы и применения для лечения диабета и связанных состояний посредством контроля уровня глюкозы крови | |
| MX2010005631A (es) | Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades. | |
| PH12013500892B1 (en) | Composition for use in the prevention and\or treatment of skin conditions and skin diseases | |
| EA201270767A1 (ru) | Терапия на основе лигандов хемосенсорных рецепторов | |
| MX336412B (es) | Nuevos analogos de glucagon. | |
| MX2015014408A (es) | Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico. | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| AR097178A1 (es) | Diagnóstico y terapias anticáncer que comprenden células madre cancerosas | |
| EA201590655A8 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| EA201391581A1 (ru) | Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| UA113849C2 (xx) | Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу | |
| FI20135152A7 (fi) | Farmaseuttinen yhdistelmäkoostumus ja menetelmiä diabeteksen ja metabolisten sairauksien hoidossa | |
| BR112015006656A8 (pt) | composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos | |
| EA201791898A1 (ru) | Новые антитела, связывающиеся с tfpi, и содержащая их композиция | |
| BR112017007138A2 (pt) | composto, medicamento, métodos para reduzir proteína 4 de ligação ao retinol e para a profilaxia ou o tratamento de degeneração macular e/ou uma doença, e, uso de um composto. | |
| MX2016007989A (es) | Derivados de oxindol, preparacion de los mismos y uso terapeutico en el tratamiento de enfermedades relacionadas con ampk. | |
| BR112015019919A2 (pt) | compostos bicíclicos | |
| BR112014030534A2 (pt) | composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada | |
| MX2009010374A (es) | Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos. | |
| EA202091446A1 (ru) | Способы лечения хронических воспалительных заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |